gemfibrozil has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Bruin, TW; Erkelens, DW; Jansen, GH; Smit, JW | 1 |
| Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD | 1 |
| Betteridge, DJ; Durrington, PN; Fairhurst, GJ; Jackson, G; McEwan, MS; McInnes, GT; Miller, JP; Mir, MA; Reckless, JP; Rees-Jones, DI | 1 |
| Glueck, CJ; Lang, JE; Wang, P | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| De Bruin, TW; Eekhoff, EM; Erkelens, DW; Glatz, J; Smit, JW | 1 |
| Antoniadis, A; Gakis, D; Imvrios, G; Miserlis, G; Papagiannis, A; Papanikolaou, V; Solonaki, F; Takoudas, D; Vergoulas, G; Visvardis, G | 1 |
| Harangi, M; Paragh, G | 1 |
| Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Dejager, S; Farnier, M; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Brun, ME; Funk, C; Noé, J; Portmann, R | 1 |
| Fan, J; Jiang, L; Kong, X; Li, Z; Wu, T; Yuan, H | 1 |
2 review(s) available for gemfibrozil and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Lipid-lowering agents for nephrotic syndrome.
Topics: Adult; Child; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Nephrotic Syndrome; Randomized Controlled Trials as Topic; Simvastatin | 2013 |
5 trial(s) available for gemfibrozil and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Topics: Anticholesteremic Agents; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Double-Blind Method; Drug Combinations; Exercise Test; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Middle Aged; Muscle, Skeletal; Myoglobin; Placebos; Prospective Studies; Triglycerides | 1995 |
Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Stenosis; Coronary Artery Disease; Coronary Disease; Cross-Over Studies; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Placebos; Safety; Triglycerides | 1995 |
Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins; Male; Middle Aged; Treatment Outcome | 1994 |
Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention.
Topics: Double-Blind Method; Drug Therapy, Combination; Exercise; Exercise Test; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Infant, Newborn; Lipids; Male; Middle Aged; Muscle Proteins; Reference Values; Triglycerides | 1999 |
Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Creatinine; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Kidney Transplantation; Male; Middle Aged; Transplantation, Homologous; Triglycerides | 2000 |
6 other study(ies) available for gemfibrozil and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Indoles; Lovastatin; Male; Middle Aged; Neuromuscular Diseases; Simvastatin; Thyroxine | 1996 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged | 2003 |
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Retrospective Studies; Sex Factors; Treatment Outcome; Triglycerides | 2003 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Topics: Animals; Anticholesteremic Agents; Biological Transport; Cell Line; CHO Cells; Chromans; Cricetinae; Cricetulus; Drug Interactions; Estrone; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Protein Binding; Recombinant Proteins; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Taurocholic Acid; Thiazolidinediones; Troglitazone | 2007 |